High grade adverse event reporting and enrolment in gynecologic oncology clinical trials
Copyright © 2024 Elsevier Inc. All rights reserved..
OBJECTIVE: The primary objective is to assess factors associated with treatment related high grade (CTCAE grade ≥ 3) adverse event (AE) reporting among participants in gynecologic oncology clinical trials.
METHODS: All AEs recorded in the Princess Margaret Clinical Trial adverse event database between 01/2016 and 12/2018 were evaluated. Gynecologic oncology clinical trials assessing systemic therapy were included. Inferential statistics on risk factors of related grade ≥ 3 adverse event reporting and GEE logistic models with Odds Ratios (OR) were performed. Multivariable analysis adjusting for age, clinical trial phase, sponsor, and therapy type.
RESULTS: The gynecology cancer clinical trials accrued 317 unique patients (359 nested on trials) in 42 systemic therapy trials. In the period, 17,175 related AEs were reported in the gynecological cancer trials, 7.4% were grade ≥ 3. On multivariable analysis, no odds differences of grade ≥ 3 related AEs were detected according to study phase. Patients in immunotherapy clinical trials had lower odds of related grade ≥ 3 AEs than patients on targeted or other therapy (adjusted OR [aOR] 0.43; 95% CI 0.24-0.75). There was greater odds of related grade ≥ 3 AEs in clinical trials assessing combination vs single therapeutics (aOR 2.26, 95% CI 1.34-3.80). Patients aged ≥65 (aOR 1.77; 95% CI 1.08-2.89) had greater odds of related grade ≥ 3 AEs than patients aged 50 to 65 years. When compared to other disease sites, the odds of having a grade ≥ 3 related AE reported in gynecology clinical trials was no different.
CONCLUSIONS: In this cohort, factors influencing the odds of related grade ≥ 3 AE reporting in gynecologic trials included type of therapy and age. The study phase did not correlate with odds of high-grade AE reporting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
|---|---|
| Enthalten in: |
Gynecologic oncology - 185(2024) vom: 10. Feb., Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Madariaga, Ainhoa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse event |
|---|
| Anmerkungen: |
Date Revised 11.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ygyno.2024.02.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368315738 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368315738 | ||
| 003 | DE-627 | ||
| 005 | 20240212232222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240212s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2024.02.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1289.xml |
| 035 | |a (DE-627)NLM368315738 | ||
| 035 | |a (NLM)38342004 | ||
| 035 | |a (PII)S0090-8258(24)00083-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Madariaga, Ainhoa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High grade adverse event reporting and enrolment in gynecologic oncology clinical trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: The primary objective is to assess factors associated with treatment related high grade (CTCAE grade ≥ 3) adverse event (AE) reporting among participants in gynecologic oncology clinical trials | ||
| 520 | |a METHODS: All AEs recorded in the Princess Margaret Clinical Trial adverse event database between 01/2016 and 12/2018 were evaluated. Gynecologic oncology clinical trials assessing systemic therapy were included. Inferential statistics on risk factors of related grade ≥ 3 adverse event reporting and GEE logistic models with Odds Ratios (OR) were performed. Multivariable analysis adjusting for age, clinical trial phase, sponsor, and therapy type | ||
| 520 | |a RESULTS: The gynecology cancer clinical trials accrued 317 unique patients (359 nested on trials) in 42 systemic therapy trials. In the period, 17,175 related AEs were reported in the gynecological cancer trials, 7.4% were grade ≥ 3. On multivariable analysis, no odds differences of grade ≥ 3 related AEs were detected according to study phase. Patients in immunotherapy clinical trials had lower odds of related grade ≥ 3 AEs than patients on targeted or other therapy (adjusted OR [aOR] 0.43; 95% CI 0.24-0.75). There was greater odds of related grade ≥ 3 AEs in clinical trials assessing combination vs single therapeutics (aOR 2.26, 95% CI 1.34-3.80). Patients aged ≥65 (aOR 1.77; 95% CI 1.08-2.89) had greater odds of related grade ≥ 3 AEs than patients aged 50 to 65 years. When compared to other disease sites, the odds of having a grade ≥ 3 related AE reported in gynecology clinical trials was no different | ||
| 520 | |a CONCLUSIONS: In this cohort, factors influencing the odds of related grade ≥ 3 AE reporting in gynecologic trials included type of therapy and age. The study phase did not correlate with odds of high-grade AE reporting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse event | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Social network | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Toxicity | |
| 700 | 1 | |a Cole, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Pittman, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Grant, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Dhani, Neesha C |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Bowering, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Sellman, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Oza, Amit M |e verfasserin |4 aut | |
| 700 | 1 | |a Lheureux, Stephanie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologic oncology |d 1972 |g 185(2024) vom: 10. Feb., Seite 1-7 |w (DE-627)NLM000614610 |x 1095-6859 |7 nnns |
| 773 | 1 | 8 | |g volume:185 |g year:2024 |g day:10 |g month:02 |g pages:1-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ygyno.2024.02.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 185 |j 2024 |b 10 |c 02 |h 1-7 | ||